Welcome to LookChem.com Sign In|Join Free
  • or
Benzenamine, 4-[2-(methylsulfonyl)ethyl]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

596131-24-7

Post Buying Request

596131-24-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

596131-24-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 596131-24-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,9,6,1,3 and 1 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 596131-24:
(8*5)+(7*9)+(6*6)+(5*1)+(4*3)+(3*1)+(2*2)+(1*4)=167
167 % 10 = 7
So 596131-24-7 is a valid CAS Registry Number.

596131-24-7Downstream Products

596131-24-7Relevant academic research and scientific papers

Treatment Method

-

, (2009/01/20)

The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Combination therapies for the treatment of ocular neovascular disorders are also encompassed.

5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE

-

Page/Page column 91-92, (2008/12/05)

The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a salt, stereoisomer, tautomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form thereof, wherein A, Y, Z, R101 and R200 are described in the specification.

CANCER TREATMENT METHOD

-

, (2010/02/14)

A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same.

CHEMICAL PROCESS

-

Page 49-50, (2010/02/04)

A process for the preparation of pyrimidine derivatives, which are useful as VEGFR2 inhibitors is described herein. The described invention also includes pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 596131-24-7